Related Experiment Video
Updated: Mar 16, 2026
05:59
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
Published on: October 20, 2023
3.3K
Geriatric syndromes: How to treat
Matteo Cesari1,2, Emanuele Marzetti3, Marco Canevelli4
1a Gérontopôle , Centre Hospitalier Universitaire de Toulouse , Toulouse , France.
Virulence
|August 20, 2016
Summary
People with HIV are aging faster biologically due to health risks. Geriatric care models may help manage aging issues in HIV patients, improving their quality of life.
Area of Science:
- Gerontology and Infectious Diseases
- Geriatric Medicine
- HIV/AIDS Research
Background:
- Improved survival rates for HIV-infected individuals due to advanced treatments.
- HIV-infected persons exhibit accelerated biological aging compared to chronological age.
- This accelerated aging is linked to clinical, social, and behavioral risk factors.
Purpose of the Study:
- To explore the parallels between accelerated aging in HIV and typical aging.
- To discuss the potential benefits of geriatric care models for HIV-positive individuals.
- To propose strategies for managing geriatric syndromes prevalent in the HIV population.
Main Methods:
- Review of current literature on HIV, aging, and geriatric care.
- Analysis of clinical, social, and behavioral factors contributing to accelerated aging in HIV.
- Discussion of adapted care models integrating geriatric principles for HIV management.
Main Results:
- HIV infection serves as a model for studying accelerated and accentuated aging.
- HIV-positive individuals often present with age-associated conditions and frailty.
- Existing geriatric care strategies can be adapted for managing complex needs in HIV patients.
Conclusions:
- A shift from disease-specific to a multidisciplinary, frailty-focused approach is crucial.
- Integrated geriatric care models can enhance the management of aging-related issues in HIV.
- Adapting geriatric care principles offers a promising avenue for improving health outcomes in aging HIV populations.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
340
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
340
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
308
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
308
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
316
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
316
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
788
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
788
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
298
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
298